Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445502 | 0.70 | HPD (0.56) | HPDLMNAHTT | |
| SCHEMBL6992951 | 0.67 | HPGD (0.46) | HPD | |
| SCHEMBL3070200 | 0.66 | IDO1 (0.71) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL79058 | 0.66 | IDO1 (0.58) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL6793063 | 0.66 | MEN1 (0.33) | LMNA | |
| SCHEMBL8464007 | 0.66 | KMT2A (0.41) | HPDLMNATSHRHTT | |
| Hydrochloric Acid SCHEMBL11629727 | 0.65 | IDO1 (0.59) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL2499860 | 0.65 | IDO1 (0.56) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL2364065 | 0.65 | IDO1 (0.69) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL4829383 | 0.64 | IDO1 (0.58) | IDO1NOS3NOS1NOS2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | HPD 3425/4885IDO1 2548/4885NOS3 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.